Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-06-16 5:21 pm Unchanged | 2023-06-15 | 13D | Cazoo Group Ltd CZOO | Farallon Capital Partners, L.P. | 10,000 2.600% | 0 (Unchanged) | Filing History |
| 2023-06-02 4:59 pm Purchase | 2023-05-31 | 13D | Exelixis, Inc. EXEL | Farallon Capital Partners, L.P. | 25,860,000 7.900% | 2,394,000 (+10.20%) | Filing History |
| 2023-05-16 5:25 pm Unchanged | 2023-05-12 | 13D | Cazoo Group Ltd CZOO | Farallon Capital Partners, L.P. | 10,000 2.600% | 0 (Unchanged) | Filing History |
| 2023-04-27 5:28 pm Unchanged | 2023-04-25 | 13D | Cazoo Group Ltd CZOO | Farallon Capital Partners, L.P. | 10,000 2.600% | 0 (Unchanged) | Filing History |
| 2023-04-06 8:54 pm Unchanged | 2023-04-05 | 13D | Exelixis, Inc. EXEL | Farallon Capital Partners, L.P. | 23,466,000 7.200% | 0 (Unchanged) | Filing History |
| 2023-04-06 4:58 pm Purchase | 2023-03-29 | 13G | Forest Road Acquisition Corp. II FRXB | Farallon Capital Partners, L.P. | 400,000 8.900% | 400,000 (New Position) | Filing History |
| 2023-03-27 4:33 pm Unchanged | 2023-03-23 | 13D | Exelixis, Inc. EXEL | Farallon Capital Partners, L.P. | 23,466,000 7.200% | 0 (Unchanged) | Filing History |
| 2023-03-24 1:34 pm Purchase | 2023-03-17 | 13D | Cazoo Group Ltd CZOO | Farallon Capital Partners, L.P. | 10,000 2.500% | 10,000 (New Position) | Filing History |
| 2023-03-20 4:39 pm Purchase | 2023-03-09 | 13D | Exelixis, Inc. EXEL | Farallon Capital Partners, L.P. | 23,466,000 7.200% | 23,466,000 (New Position) | Filing History |
| 2023-02-17 3:20 pm Purchase | 2023-02-08 | 13G | AVROBIO, Inc. AVRO | Farallon Capital Partners, L.P. | 259,667 7.100% | 259,667 (New Position) | Filing History |
| 2023-02-14 08:27 am Sale | 2022-12-31 | 13G | Beam Therapeutics Inc. BEAM | Farallon Capital Partners, L.P. | 3,399,921 4.800% | -151,850 (-4.28%) | Filing History |
| 2023-02-09 4:55 pm Unchanged | 2022-12-31 | 13G | Shelter Acquisition Corporation I SHQA | Farallon Capital Partners, L.P. | 0 0.000% | 0 (Unchanged) | Filing History |
| 2023-02-09 4:55 pm Purchase | 2022-12-31 | 13G | Swiftmerge Acquisition Corp. IVCP | Farallon Capital Partners, L.P. | 2,205,000 9.700% | 2,205,000 (New Position) | Filing History |
| 2023-02-09 4:54 pm Purchase | 2022-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX | Farallon Capital Partners, L.P. | 5,055,102 9.990% | 5,055,102 (New Position) | Filing History |
| 2023-02-07 5:10 pm Sale | 2022-12-31 | 13G | Better Therapeutics, Inc. BTTX | Farallon Capital Partners, L.P. | 813,556 3.400% | -536,444 (-39.74%) | Filing History |
| 2023-02-07 5:09 pm Sale | 2022-12-31 | 13G | Clarivate Plc CLVT | Farallon Capital Partners, L.P. | 15,177,433 2.300% | -20,148,467 (-57.04%) | Filing History |
| 2023-02-07 5:09 pm Purchase | 2022-12-31 | 13G | AMYRIS INC AMRSQ | Farallon Capital Partners, L.P. | 1,000,000 0.300% | 1,000,000 (New Position) | Filing History |
| 2023-02-06 4:20 pm Unchanged | 2022-12-31 | 13G | SEP Acquisition Corp. SEPA | Farallon Capital Partners, L.P. | 0 0.000% | 0 (Unchanged) | Filing History |
| 2023-02-06 09:06 am Purchase | 2022-12-31 | 13G | Enanta Pharmaceuticals, Inc. ENTA | Farallon Capital Partners, L.P. | 1,550,000 7.500% | 1,550,000 (New Position) | Filing History |
| 2023-02-03 5:16 pm Purchase | 2022-12-31 | 13G | Savara Inc. SVRA | Farallon Capital Partners, L.P. | 11,532,622 9.990% | 11,532,622 (New Position) | Filing History |